search

Active clinical trials for "Purpura, Thrombocytopenic, Idiopathic"

Results 141-150 of 380

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary...

Primary Immunodeficiency Diseases (PID)Immune Thrombocytopenic Purpura (ITP)1 more

The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.

Completed16 enrollment criteria

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune...

PurpuraThrombocytopaenic1 more

This study is a double-blind, randomized, placebo-controlled, parallel group, repeat-dose, study conducted in two parts (Part A and Part B) examining 30, 50, and 75 mg doses of SB-497115-GR as a treatment for patients with ITP who have failed prior therapy. The study is designed to determine the proportion of patients with a platelet count =50,000/µL after 42 days. In Part B, 99 newly-recruited subjects will be randomized to one of two dosing arms in a 2:1 ratio of active:placebo. During the 6 week study period, subjects will start on placebo or active drug (50 mg) and may have a dose increase to 75 mg based upon their platelet count at day 22.

Completed8 enrollment criteria

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura...

ThrombocytopeniaIdiopathic Thrombocytopenic Purpura

The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response. This study will also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531.

Completed29 enrollment criteria

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura...

ThrombocytopeniaIdiopathic Thrombocytopenic Purpura

The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response. This study will also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531.

Completed28 enrollment criteria

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia...

Immune Thrombocytopenia (ITP)

The objective of evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia.

Completed13 enrollment criteria

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study...

Primary Immune Thrombocytopenia

The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.

Completed8 enrollment criteria

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity...

Autoimmune Lymphoproliferative SyndromeAutoimmune Cytopenia19 more

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

Not yet recruiting15 enrollment criteria

The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia...

Immune Thrombocytopenia

Randomized, open-label, multicenter study to compare the efficacy and safety of ATRA plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

Completed13 enrollment criteria

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment...

ITP

This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).

Completed14 enrollment criteria

Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine

Primary Immune Thrombocytopenia

The purpose of this study is to assess the ability of Atorvastatin and N-acetyl cysteine to elevate the blood (serum) platelet count in patients with Immune Thrombocytopenia as a mean of a new treatment.

Completed14 enrollment criteria
1...141516...38

Need Help? Contact our team!


We'll reach out to this number within 24 hrs